Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients

Research output: Contribution to journalArticle

Abstract

This study aimed to identify circulating miRNAs as novel non-invasive biomarkers for prognosis and vandetanib response in advanced medullary thyroid cancer (MTC) patients. We prospectively recruited two independent cohorts of locally advanced/metastatic MTC patients including a subgroup of vandetanib-treated subjects: a discovery cohort (n = 20), including matched plasma/tissue samples (n = 17/20), and a validation cohort, yielding only plasma samples (n = 17). Plasma samples from healthy subjects (n = 36) and MTC patients in remission (n = 9) were used as controls. MTC (n = 17 from 8 patients included in discovery cohort) and non-neoplastic thyroid specimens (n = 3) were assessed by microarray profiling to identify candidate circulating miRNAs. qRT-PCR and in situ hybridization were carried out to validate the expression and localization of a selected miRNA within tissues, and qRT-PCR was also performed to measure miRNA levels in plasma samples. By microarray analysis, we identified 51 miRNAs differentially expressed in MTC. The most overexpressed miR, miR-375, was highly expressed by C cells compared to other thyroid cells, and more expressed in MTC than in reactive C-cell hyperplasia. MTC patients had significantly higher miR-375 plasma levels than healthy controls (P 
Original languageItalian
Pages (from-to)217-231
Number of pages15
JournalEndocrine-Related Cancer
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 2018

Cite this

@article{d7c70f2014b24b59b5c6d8f28530e280,
title = "Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients",
abstract = "This study aimed to identify circulating miRNAs as novel non-invasive biomarkers for prognosis and vandetanib response in advanced medullary thyroid cancer (MTC) patients. We prospectively recruited two independent cohorts of locally advanced/metastatic MTC patients including a subgroup of vandetanib-treated subjects: a discovery cohort (n = 20), including matched plasma/tissue samples (n = 17/20), and a validation cohort, yielding only plasma samples (n = 17). Plasma samples from healthy subjects (n = 36) and MTC patients in remission (n = 9) were used as controls. MTC (n = 17 from 8 patients included in discovery cohort) and non-neoplastic thyroid specimens (n = 3) were assessed by microarray profiling to identify candidate circulating miRNAs. qRT-PCR and in situ hybridization were carried out to validate the expression and localization of a selected miRNA within tissues, and qRT-PCR was also performed to measure miRNA levels in plasma samples. By microarray analysis, we identified 51 miRNAs differentially expressed in MTC. The most overexpressed miR, miR-375, was highly expressed by C cells compared to other thyroid cells, and more expressed in MTC than in reactive C-cell hyperplasia. MTC patients had significantly higher miR-375 plasma levels than healthy controls (P ",
author = "Paola Romeo and Carla Colombo and Roberta Granata and Giuseppina Calareso and Gualeni, {Ambra Vittoria} and Matteo Dugo and {De Cecco}, Loris and Rizzetti, {Maria Grazia} and Angela Zanframundo and Antonella Aiello and Carcangiu, {Maria Luisa} and Annunziata Gloghini and Stefano Ferrero and Lisa Licitra and Angela Greco and Laura Fugazzola and Locati, {Laura Deborah} and Borrello, {Maria Grazia}",
note = "{\circledC} 2018 Society for Endocrinology.",
year = "2018",
month = "3",
doi = "10.1530/ERC-17-0389",
language = "Italian",
volume = "25",
pages = "217--231",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients

AU - Romeo, Paola

AU - Colombo, Carla

AU - Granata, Roberta

AU - Calareso, Giuseppina

AU - Gualeni, Ambra Vittoria

AU - Dugo, Matteo

AU - De Cecco, Loris

AU - Rizzetti, Maria Grazia

AU - Zanframundo, Angela

AU - Aiello, Antonella

AU - Carcangiu, Maria Luisa

AU - Gloghini, Annunziata

AU - Ferrero, Stefano

AU - Licitra, Lisa

AU - Greco, Angela

AU - Fugazzola, Laura

AU - Locati, Laura Deborah

AU - Borrello, Maria Grazia

N1 - © 2018 Society for Endocrinology.

PY - 2018/3

Y1 - 2018/3

N2 - This study aimed to identify circulating miRNAs as novel non-invasive biomarkers for prognosis and vandetanib response in advanced medullary thyroid cancer (MTC) patients. We prospectively recruited two independent cohorts of locally advanced/metastatic MTC patients including a subgroup of vandetanib-treated subjects: a discovery cohort (n = 20), including matched plasma/tissue samples (n = 17/20), and a validation cohort, yielding only plasma samples (n = 17). Plasma samples from healthy subjects (n = 36) and MTC patients in remission (n = 9) were used as controls. MTC (n = 17 from 8 patients included in discovery cohort) and non-neoplastic thyroid specimens (n = 3) were assessed by microarray profiling to identify candidate circulating miRNAs. qRT-PCR and in situ hybridization were carried out to validate the expression and localization of a selected miRNA within tissues, and qRT-PCR was also performed to measure miRNA levels in plasma samples. By microarray analysis, we identified 51 miRNAs differentially expressed in MTC. The most overexpressed miR, miR-375, was highly expressed by C cells compared to other thyroid cells, and more expressed in MTC than in reactive C-cell hyperplasia. MTC patients had significantly higher miR-375 plasma levels than healthy controls (P 

AB - This study aimed to identify circulating miRNAs as novel non-invasive biomarkers for prognosis and vandetanib response in advanced medullary thyroid cancer (MTC) patients. We prospectively recruited two independent cohorts of locally advanced/metastatic MTC patients including a subgroup of vandetanib-treated subjects: a discovery cohort (n = 20), including matched plasma/tissue samples (n = 17/20), and a validation cohort, yielding only plasma samples (n = 17). Plasma samples from healthy subjects (n = 36) and MTC patients in remission (n = 9) were used as controls. MTC (n = 17 from 8 patients included in discovery cohort) and non-neoplastic thyroid specimens (n = 3) were assessed by microarray profiling to identify candidate circulating miRNAs. qRT-PCR and in situ hybridization were carried out to validate the expression and localization of a selected miRNA within tissues, and qRT-PCR was also performed to measure miRNA levels in plasma samples. By microarray analysis, we identified 51 miRNAs differentially expressed in MTC. The most overexpressed miR, miR-375, was highly expressed by C cells compared to other thyroid cells, and more expressed in MTC than in reactive C-cell hyperplasia. MTC patients had significantly higher miR-375 plasma levels than healthy controls (P 

U2 - 10.1530/ERC-17-0389

DO - 10.1530/ERC-17-0389

M3 - Articolo

VL - 25

SP - 217

EP - 231

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 3

ER -